Medicamen Biotech Limited (MEDICAMEQ.NS)
INR 557.3
(0.3%)
INR 557.3
(0.3%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 308.17 Million INR | 27.43% |
| 2022 | 241.82 Million INR | -6.25% |
| 2021 | 257.95 Million INR | 37.07% |
| 2020 | 188.19 Million INR | 64.05% |
| 2019 | 114.71 Million INR | -2.41% |
| 2018 | 117.55 Million INR | -18.91% |
| 2017 | 144.96 Million INR | -30.14% |
| 2016 | 207.51 Million INR | 1.45% |
| 2015 | 204.54 Million INR | -1.26% |
| 2014 | 207.15 Million INR | 34.45% |
| 2013 | 154.07 Million INR | -8.82% |
| 2012 | 168.98 Million INR | 30.76% |
| 2011 | 129.22 Million INR | 31.72% |
| 2010 | 98.1 Million INR | -22.78% |
| 2009 | 127.04 Million INR | 44.82% |
| 2008 | 87.72 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 290.2 Million INR | 0.0% |
| 2023 Q4 | 308.17 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 308.17 Million INR | 27.43% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 241.82 Million INR | -6.25% |
| 2022 Q2 | 284.88 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 241.82 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 257.95 Million INR | 37.07% |
| 2021 Q4 | 257.95 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 251.24 Million INR | 0.0% |
| 2020 FY | 188.19 Million INR | 64.05% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 183.4 Million INR | 0.0% |
| 2020 Q4 | 188.19 Million INR | 0.0% |
| 2019 Q4 | 114.71 Million INR | 0.0% |
| 2019 FY | 114.71 Million INR | -2.41% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 52.38 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 117.55 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 31.43 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 117.55 Million INR | -18.91% |
| 2017 Q4 | 144.96 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 165.59 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 144.96 Million INR | -30.14% |
| 2016 Q2 | 141.1 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 207.51 Million INR | 0.0% |
| 2016 FY | 207.51 Million INR | 1.45% |
| 2015 Q2 | 193.53 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 204.54 Million INR | -1.26% |
| 2015 Q4 | 204.54 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q4 | 207.15 Million INR | 0.0% |
| 2014 FY | 207.15 Million INR | 34.45% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 159.83 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q4 | 154.07 Million INR | 0.0% |
| 2013 Q2 | 165.97 Million INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 154.07 Million INR | -8.82% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q4 | 168.98 Million INR | 0.0% |
| 2012 FY | 168.98 Million INR | 30.76% |
| 2012 Q2 | 166.72 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 FY | 129.22 Million INR | 31.72% |
| 2011 Q4 | 129.22 Million INR | 0.0% |
| 2010 FY | 98.1 Million INR | -22.78% |
| 2009 FY | 127.04 Million INR | 44.82% |
| 2008 FY | 87.72 Million INR | 0.0% |
| 2008 Q4 | 87.72 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 78.457% |
| Innova Captab Limited | 2.45 Billion INR | 87.427% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 90.741% |
| Sakar Healthcare Limited | 793.51 Million INR | 61.164% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.536% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 96.953% |
| Divi's Laboratories Limited | 30 Million INR | -927.24% |
| Ind-Swift Limited | 10.13 Billion INR | 96.961% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -570.201% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 68.711% |
| Morepen Laboratories Limited | 289.99 Million INR | -6.269% |
| Mankind Pharma Limited | 2.07 Billion INR | 85.125% |
| Sequent Scientific Limited | 4.87 Billion INR | 93.681% |
| Wanbury Limited | 1.16 Billion INR | 73.544% |
| Laurus Labs Limited | 25.77 Billion INR | 98.804% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 95.151% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -79.713% |
| Alembic Limited | 91.5 Million INR | -236.8% |
| Hikal Limited | 8.17 Billion INR | 96.231% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 93.995% |
| Neuland Laboratories Limited | 953.89 Million INR | 67.693% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 91.84% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 97.496% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | 5.93% |
| Themis Medicare Limited | 957.92 Million INR | 67.829% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 96.168% |
| Lupin Limited | 29.21 Billion INR | 98.945% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -1683.093% |
| Wockhardt Limited | 23.56 Billion INR | 98.692% |
| Vaishali Pharma Limited | 134.91 Million INR | -128.414% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 89.196% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -244.673% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.159% |
| FDC Limited | 205.18 Million INR | -50.192% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 98.461% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | 2.621% |
| Eris Lifesciences Limited | 27.81 Billion INR | 98.892% |
| Venus Remedies Limited | 413.3 Million INR | 25.436% |
| ZIM Laboratories Limited | 1.08 Billion INR | 71.682% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 69.133% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Gufic Biosciences Limited | 3.32 Billion INR | 90.743% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -1464.325% |
| Windlas Biotech Limited | 36.41 Million INR | -746.394% |
| Shilpa Medicare Limited | 9.37 Billion INR | 96.712% |
| Orchid Pharma Limited | 1.35 Billion INR | 77.203% |
| Albert David Limited | 33.24 Million INR | -827.056% |
| Aarti Drugs Limited | 5.64 Billion INR | 94.539% |
| Ajanta Pharma Limited | 352.8 Million INR | 12.65% |
| Hester Biosciences Limited | 2.44 Billion INR | 87.39% |
| Bal Pharma Limited | 1.39 Billion INR | 77.932% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 52.586% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 99.059% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -2788.751% |
| Procter & Gamble Health Limited | 95.6 Million INR | -222.356% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | 1.707% |
| Granules India Limited | 13.15 Billion INR | 97.657% |
| Valiant Laboratories Limited | 767.08 Million INR | 59.826% |
| Alkem Laboratories Limited | 14.18 Billion INR | 97.827% |
| Unichem Laboratories Limited | 2.47 Billion INR | 87.549% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -26.355% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -6921.463% |
| Medico Remedies Limited | 80.5 Million INR | -282.803% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -85.405% |
| Ipca Laboratories Limited | 14.38 Billion INR | 97.857% |
| Brooks Laboratories Limited | 56.41 Million INR | -446.22% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 57.486% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.942% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.234% |
| NATCO Pharma Limited | 3.71 Billion INR | 91.698% |
| Suven Life Sciences Limited | 7.09 Million INR | -4242.285% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 84.068% |
| Strides Pharma Science Limited | 25.16 Billion INR | 98.776% |
| Indoco Remedies Limited | 6.71 Billion INR | 95.414% |
| Alpa Laboratories Limited | 52.46 Million INR | -487.386% |
| Lasa Supergenerics Limited | 220.76 Million INR | -39.595% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 49.604% |